MedTrace Logo

Treatment Protocol for Clofazamine in the Long Term Treatment of Leprosy

NCT00852345 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2015-04-03

No results posted yet for this study

Summary

Clofazimine has shown effectiveness in the treatment of leprosy for many years. The World Health Organization and the National Hansen's Disease Program consider clofazamine to be standard therapy for treatment of multibacillary leprosy. In recent years, the availability of the drug has become limited and is currently available only under a research protocol and is considered "investigational." Use of Clofazamine in patients presenting with lepromatous leprosy is necessary for patients exhibiting nerve involvement or lesions resistant to other therapies. This drug will be used prospectively for patients who require treatment of leprosy as deemed appropriate by a Kaiser Permanente Southern California physician.

Conditions

  • Leprosy

Interventions

DRUG

clofazamine

clofazamine 50mg po qday (duration varies according to physician)

Sponsors & Collaborators

  • Health Resources and Services Administration (HRSA)

    collaborator FED

  • Kaiser Permanente

    lead OTHER

Principal Investigators

  • Arnold M Henson, MD · Kaiser Permanente

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00852345 on ClinicalTrials.gov